J&J's Tremfya shows durable efficacy in Phase III extension for plaque psoriasis
The Janssen Research & Development LLC unit of Johnson & Johnson (NYSE:JNJ) reported 2-year data from the open-label extension of the double-blind, international Phase III VOYAGE 1 trial of Tremfya guselkumab (CNTO 1959) showing that the drug maintained long-term efficacy in patients with moderate to severe plaque psoriasis.
In the 837-patient trial, 82.1% of patients who received subcutaneous Tremfya at weeks 0 and 4 and then every 8 weeks for 100 weeks had 90% skin clearance as measured by the Psoriasis Area and Severity Index (PASI 90). Additionally, 82.4% of patients achieved an Investigator’s Global Assessment (IGA) score of cleared or minimal disease at week 100...
BCIQ Target Profiles